Use of Recombinant Human Erythropoietin in Allogeneic Bone Marrow Transplant Donor/Recipient Pairs
In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-...
Gespeichert in:
| Veröffentlicht in: | Blood 1994-04, Vol.83 (7), p.1952-1957 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1957 |
|---|---|
| container_issue | 7 |
| container_start_page | 1952 |
| container_title | Blood |
| container_volume | 83 |
| creator | Mitus, A. Jacqueline Antin, Joseph H. Rutherford, Cynthia J. McGarigle, Carol J. Goldberg, Mark A. |
| description | In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count ≥104/μL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment. |
| doi_str_mv | 10.1182/blood.V83.7.1952.1952 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76417793</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120738395</els_id><sourcerecordid>76417793</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-af6f9ece884831dc2c9c0591b6edf250c0f41371f385e1db8d06cb8843883abd3</originalsourceid><addsrcrecordid>eNqFkNtKxDAQhoMo63p4hIVeiHddk6ZN0yvR9QiKIrvehjSZaKRtatJVfHuzB7wVwoQw3z8ZPoQmBE8J4dlZ3Tinp6-cTsspqYpsXXbQmBQZTzHO8C4aY4xZmlcl2UcHIXxgTHKaFSM04iTPGCNjVC8CJM4kL6BcW9tOdkNyt2xll1z7n-Hdu95ZGGyXxHPRNO4NOrAquXQdJI_Se_edzL3sQt-skleuc_4szrK9hfh-ltaHI7RnZBPgeHsfosXN9Xx2lz483d7PLh5SRRkfUmmYqUAB5zmnRKtMVQoXFakZaJMVWGGTE1oSQ3kBRNdcY6bqSFPOqaw1PUSnm7m9d59LCINobVDQxM3ALYMoWU7KsqIRLDag8i4ED0b03rbS_wiCxcqtWLsV0a0oxUrrusTcZPvBsm5B_6W2MmP_ZNuXQcnGRC_Khj8sxwUr19j5BoMo48uCF0FFWwq09aAGoZ39Z5FfLSyZ0w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76417793</pqid></control><display><type>article</type><title>Use of Recombinant Human Erythropoietin in Allogeneic Bone Marrow Transplant Donor/Recipient Pairs</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Mitus, A. Jacqueline ; Antin, Joseph H. ; Rutherford, Cynthia J. ; McGarigle, Carol J. ; Goldberg, Mark A.</creator><creatorcontrib>Mitus, A. Jacqueline ; Antin, Joseph H. ; Rutherford, Cynthia J. ; McGarigle, Carol J. ; Goldberg, Mark A.</creatorcontrib><description>In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count ≥104/μL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.V83.7.1952.1952</identifier><identifier>PMID: 8142661</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Bone Marrow Transplantation ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Erythrocyte Transfusion ; Erythropoietin - therapeutic use ; Female ; Humans ; Male ; Medical sciences ; Recombinant Proteins - therapeutic use ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation, Homologous</subject><ispartof>Blood, 1994-04, Vol.83 (7), p.1952-1957</ispartof><rights>1994 American Society of Hematology</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-af6f9ece884831dc2c9c0591b6edf250c0f41371f385e1db8d06cb8843883abd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4056761$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8142661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mitus, A. Jacqueline</creatorcontrib><creatorcontrib>Antin, Joseph H.</creatorcontrib><creatorcontrib>Rutherford, Cynthia J.</creatorcontrib><creatorcontrib>McGarigle, Carol J.</creatorcontrib><creatorcontrib>Goldberg, Mark A.</creatorcontrib><title>Use of Recombinant Human Erythropoietin in Allogeneic Bone Marrow Transplant Donor/Recipient Pairs</title><title>Blood</title><addtitle>Blood</addtitle><description>In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count ≥104/μL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.</description><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Bone Marrow Transplantation</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Erythrocyte Transfusion</subject><subject>Erythropoietin - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation, Homologous</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkNtKxDAQhoMo63p4hIVeiHddk6ZN0yvR9QiKIrvehjSZaKRtatJVfHuzB7wVwoQw3z8ZPoQmBE8J4dlZ3Tinp6-cTsspqYpsXXbQmBQZTzHO8C4aY4xZmlcl2UcHIXxgTHKaFSM04iTPGCNjVC8CJM4kL6BcW9tOdkNyt2xll1z7n-Hdu95ZGGyXxHPRNO4NOrAquXQdJI_Se_edzL3sQt-skleuc_4szrK9hfh-ltaHI7RnZBPgeHsfosXN9Xx2lz483d7PLh5SRRkfUmmYqUAB5zmnRKtMVQoXFakZaJMVWGGTE1oSQ3kBRNdcY6bqSFPOqaw1PUSnm7m9d59LCINobVDQxM3ALYMoWU7KsqIRLDag8i4ED0b03rbS_wiCxcqtWLsV0a0oxUrrusTcZPvBsm5B_6W2MmP_ZNuXQcnGRC_Khj8sxwUr19j5BoMo48uCF0FFWwq09aAGoZ39Z5FfLSyZ0w</recordid><startdate>19940401</startdate><enddate>19940401</enddate><creator>Mitus, A. Jacqueline</creator><creator>Antin, Joseph H.</creator><creator>Rutherford, Cynthia J.</creator><creator>McGarigle, Carol J.</creator><creator>Goldberg, Mark A.</creator><general>Elsevier Inc</general><general>The Americain Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19940401</creationdate><title>Use of Recombinant Human Erythropoietin in Allogeneic Bone Marrow Transplant Donor/Recipient Pairs</title><author>Mitus, A. Jacqueline ; Antin, Joseph H. ; Rutherford, Cynthia J. ; McGarigle, Carol J. ; Goldberg, Mark A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-af6f9ece884831dc2c9c0591b6edf250c0f41371f385e1db8d06cb8843883abd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Bone Marrow Transplantation</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Erythrocyte Transfusion</topic><topic>Erythropoietin - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation, Homologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mitus, A. Jacqueline</creatorcontrib><creatorcontrib>Antin, Joseph H.</creatorcontrib><creatorcontrib>Rutherford, Cynthia J.</creatorcontrib><creatorcontrib>McGarigle, Carol J.</creatorcontrib><creatorcontrib>Goldberg, Mark A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mitus, A. Jacqueline</au><au>Antin, Joseph H.</au><au>Rutherford, Cynthia J.</au><au>McGarigle, Carol J.</au><au>Goldberg, Mark A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Recombinant Human Erythropoietin in Allogeneic Bone Marrow Transplant Donor/Recipient Pairs</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>1994-04-01</date><risdate>1994</risdate><volume>83</volume><issue>7</issue><spage>1952</spage><epage>1957</epage><pages>1952-1957</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>In an attempt to reduce or eliminate homologous red blood cell transfusion requirements during allogeneic bone marrow transplantation (BMT), we instituted a novel program whereby recombinant human erythropoietin was administered to pairs of BMT donors and recipients. Eleven recipients and their HLA-matched donors were enrolled. Donors treated with recombinant human erythropoietin (rHuEPO) were phlebotomized a median of 6 U (range, 4 to 11 U) of blood over a 5-week period. This donor-derived blood was available to the BMT donor or recipient as needed. Transplant recipients were also treated with rHuEPO post-BMT to hasten erythropoiesis. Five of 11 BMT recipients underwent transplant receiving only donor-derived red blood cell transfusions, compared with 0 of 11 concomitant control recipients (P = .04). In addition, the time to absolute reticulocyte count ≥104/μL was statistically shorter in the rHuEPO-treated recipient group. This study serves as a paradigm for hematopoietic growth factor use in allogeneic BMT to decrease or eliminate homologous transfusion exposures and to possibly hasten hematopoietic engraftment.</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>8142661</pmid><doi>10.1182/blood.V83.7.1952.1952</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 1994-04, Vol.83 (7), p.1952-1957 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76417793 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Bone Marrow Transplantation Bone marrow, stem cells transplantation. Graft versus host reaction Erythrocyte Transfusion Erythropoietin - therapeutic use Female Humans Male Medical sciences Recombinant Proteins - therapeutic use Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation, Homologous |
| title | Use of Recombinant Human Erythropoietin in Allogeneic Bone Marrow Transplant Donor/Recipient Pairs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T02%3A58%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Recombinant%20Human%20Erythropoietin%20in%20Allogeneic%20Bone%20Marrow%20Transplant%20Donor/Recipient%20Pairs&rft.jtitle=Blood&rft.au=Mitus,%20A.%20Jacqueline&rft.date=1994-04-01&rft.volume=83&rft.issue=7&rft.spage=1952&rft.epage=1957&rft.pages=1952-1957&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.V83.7.1952.1952&rft_dat=%3Cproquest_cross%3E76417793%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76417793&rft_id=info:pmid/8142661&rft_els_id=S0006497120738395&rfr_iscdi=true |